Chairman of the Board since April 2022, member of the Board of Directors since 2021
Education: MA in comparative literature from the University of Copenhagen
Background: Worked for more than 20 years at the international management consulting firm McKinsey & Company, specializing in healthcare, biotech, pharmaceuticals and life sciences, since 2007 as a Partner and since 2013 as a Senior Partner. In that role, he has advised companies globally on strategy, growth and transformations, including drug development and innovation.
Other ongoing assignments: Board member in Immunovia AB and Rehaler ApS
Independence: Independent in relation to both the Company and executive management as well as larger shareholders
Scandion Oncology shares and warrants
6.266 shares and 128.542 warrants.